Trial
NCT06398587
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University
Condition
Locally Advanced Pancreatic Ductal Adenocarcinoma
Intervention
Onvansertib
Why stopped
Sponsor withdrawal
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-19